Real-World Data & Market Intelligence - software & AI news

Daily news on software, AI, and companies shaping real-world data & market intelligence.

Showing 58 results
A minimalist illustration of a magnifying glass over a data point, symbolizing insights in life sciences.

Jun 2, 2026

A new AI-powered intelligence solution launches for life sciences through Prezent Vivo and Nested Knowledge

A new partnership between Prezent Vivo and Nested Knowledge aims to enhance competitive intelligence for life sciences organizations by leveraging AI-driven solutions.This collaboration merges Prezent Vivo's AI-enhanced communication platform with Nested Knowledge's automated evidence synthesis capabilities through the AutoLit® platform. The goal is to address a prevalent issue in the life sciences sector: the challenge of transforming extensive scientific and competitive data into actionable in
A stethoscope on a medical chart in a dimly lit clinic room

May 29, 2026

H1 secures $40M from CVS, proving SaaS startups can still attract investment

H1, a healthcare data platform, has successfully secured a $40 million investment from CVS Health Ventures, highlighting the ongoing viability of certain SaaS startups in the current investment landscape.Despite a general trend where pre-AI era startups face challenges in attracting funding, H1's co-founder and CEO, Ariel Katz, believes that not all SaaS companies should be viewed negatively. He posits that companies focused on data provision, like H1, have unique value propositions that AI cann
A tissue sample under a microscope in a lab setting

May 26, 2026

Prezent Vivo and Nested Knowledge Partner to Bring AI-Powered Competitive Intelligence to Life Sciences Teams

Prezent Vivo and Nested Knowledge have formed a strategic partnership aimed at enhancing competitive intelligence for life sciences teams. By integrating Prezent Vivo's AI-driven communication capabilities with Nested Knowledge's evidence synthesis technology, the collaboration seeks to streamline the preparation process for medical congresses and ongoing competitive analysis.The partnership leverages Prezent Vivo's model that combines artificial intelligence with human expertise, enabling rapid
A flat design of a document with a checkmark representing evidence generation in biopharma.

May 14, 2026

Princeton Biopartners' Evexa Named Among Top Evidence Generation Software Platforms of 2026 by Life Sciences Review

Princeton Biopartners has announced that its innovative platform, Evexa, has been recognized by Life Sciences Review as one of the top evidence generation software platforms for 2026, highlighting its pivotal role in biopharma.Evexa stands out as the first AI-native solution specifically designed for Integrated Evidence Plans (IEPs) and Data Dissemination Plans (DDPs). This platform integrates various functionalities such as evidence gap analysis, study prioritization, and KPI tracking into a un
A notebook with clinical notes on a desk in a healthcare office

May 6, 2026

Dandelion Health Raises $14M Series A for Clinical Intelligence

Dandelion Health, a clinical intelligence startup based in New York, has successfully secured $14 million in a Series A funding round, led by Healthier Capital. This capital will be instrumental in enhancing its multimodal real-world data (RWD) platform, aimed at optimizing pharmaceutical drug development and clinical trials.The funding round, announced on May 5, 2026, also saw participation from Colle Capital and returning investors such as Primary Venture Partners, Moxxie Ventures, and Converg
Stylized DNA double helix with patient connection symbols

May 3, 2026

Why Tempus AI (TEM) Is Up 5.5% After Major USC Precision-Medicine Data Partnership News

Tempus AI has recently seen a 5.5% increase in its stock price following a significant collaboration with the Keck School of Medicine of USC, which aims to integrate its genomic testing and AI capabilities into a vast patient network.This partnership will enhance Tempus AI's access to real-world oncology data, bolstering its position in precision medicine. By embedding its technology across more than 1.5 million patient visits annually, Tempus aims to strengthen its data ecosystem, which is crit
A flat illustration of a tumor cell surrounded by data outlines.

Apr 30, 2026

HealthTech Innovation from Europe

Medical Evidence AI is pioneering a transformative approach in oncology by integrating real-world patient data and AI, aiming to enhance decision-making for healthcare providers while ensuring data privacy.Medical Evidence AI stands out in the healthcare landscape by combining anonymized patient data with immune status and tumor activity analyses. This platform is designed to provide physicians with a comprehensive, data-driven foundation for clinical decisions, without compromising patient priv
A blood sample in a lab setting

Apr 29, 2026

Labcorp Stock (US50540R4092): AI-Powered Platform Launch Accelerates Alzheimer's Research

Labcorp has launched an AI-driven real-world data platform in collaboration with AWS and Datavant, aimed at accelerating Alzheimer's research. This initiative, announced on April 29, 2026, positions Labcorp as a frontrunner in utilizing AI for clinical data analysis, appealing to U.S. investors interested in biotech innovations.The new platform enhances Labcorp's capabilities in real-world data analysis, which is crucial for advancing Alzheimer's research. This move aligns with a broader industr
Flat silhouette of a data chart representing oncology data monetization

Apr 29, 2026

TEM: Data Partnerships And Backlog Will Support Future Oncology Data Monetization

Recent analysis on Tempus AI indicates a mixed outlook, with price targets adjusting slightly to $72.40, reflecting updated revenue growth models and profit assumptions following Q4 results and ongoing partnerships.Analysts are divided in their views on Tempus AI, with some raising targets while others adopt a more cautious stance. The focus is primarily on the company's ability to execute partnerships and monetize its data, which are seen as vital for long-term growth. Bullish analysts highligh
An open medical file on a desk in a dimly lit office, emphasizing patient data.

Apr 25, 2026

SEQSTER CEO Ardy Arianpour on AWS Bio Discovery, fragmented health records and AI drug discovery’s missing patient layer

Ardy Arianpour, CEO of SEQSTER, highlights the vital role of patient-level data in AI-driven drug discovery, particularly in light of Amazon's recent Bio Discovery initiative.As major tech companies increasingly venture into healthcare, Amazon's Bio Discovery emphasizes the importance of integrating advanced AI with real-world patient data. Arianpour argues that while AI can generate valuable molecular hypotheses, the absence of comprehensive patient data limits its effectiveness. He stresses th